Skip to content

Doxycycline for Helicobacter Pylori Rescue Treatment

Doxycycline-containing Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment: a Randomized Controlled Trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05874570
Enrollment
368
Registered
2023-05-25
Start date
2023-06-20
Completion date
2025-10-31
Last updated
2024-12-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter Pylori Infection

Keywords

Helicobacter pylori, rescue therapy, doxycycline, tetracycline

Brief summary

Current guidelines have recommended classical bismuth-containing quadruple therapy including proton-pump inhibitor, bismuth, tetracycline, metronidazole as the empirical rescue therapy. However, tetracycline is clinically unavailable in China and the high frequency of adverse events of bismuth quadruple therapy often result in poor compliance, which limited the applicability of this recommendation. This study aimed to compare the efficacy and tolerability of a 14-day bismuth-containing quadruple rescue therapy in which tetracycline was replaced by doxycycline.

Interventions

DRUGEsomeprazole

Proton pump inhibitor

DRUGBismuth Potassium Citrate

Gastric mucosal protective drug with anti-H. pylori effect

DRUGTetracycline

Antibiotics for H. pylori eradication

DRUGDoxycycline

Antibiotics for H. pylori eradication

DRUGMetronidazole

Antibiotics for H. pylori eradication

Sponsors

Shanghai Jiao Tong University School of Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Ability and willingness to participate in the study and to sign and give informed consent * Confirmed H. pylori infection and with previous treatment failure

Exclusion criteria

* subjects naive to H. pylori treatment, * under 18 or over 80 years old * history of gastrectomy * pregnant or lactating women * severe systemic diseases or malignancy * administration of antibiotics, bismuth, antisecretory drugs, or Chinese herb medicine in the preceding 8 weeks

Design outcomes

Primary

MeasureTime frameDescription
Helicobacter pylori eradication rateSix weeks after completion of therapySix weeks after completion of therapy, H. pylori eradication was assessed by ¹³C-urea breath test. Eradication was defined as negative result from urea breath test (\<4‰) (4‰ as the cutoff value).

Secondary

MeasureTime frameDescription
Rate of adverse effectsWithin 7 days after completion of therapyThe subjects were asked to grade the severity of adverse events according to their influence on daily activities, experienced as mild (transient and well tolerated), moderate (causing discomfort and partially interfering with daily activities), or severe (causing considerable interference with daily activities)
Compliance rateWithin 7 days after completion of therapyCompliance was defined as poor when they had taken less than 80% of the total medication

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026